Zevra Therapeutics Inc (ZVRA) valuation
Zevra Therapeutics P/E ratio history
Zevra Therapeutics trades at 10.9 times its earnings over the last twelve months and 9.2 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $8.96 | $1.35 | 6.6 |
| Dec 31, 2024 | $8.34 | — | n/m |
| Dec 31, 2023 | $6.55 | — | n/m |
| Dec 31, 2022 | $4.59 | — | n/m |
| Dec 31, 2021 | $8.71 | -$2.11 | n/m |
| Dec 31, 2020 | $11.20 | -$3.21 | n/m |
| Dec 31, 2019 | $6.06 | — | n/m |
| Dec 31, 2018 | $28.48 | — | n/m |
| Dec 31, 2017 | $64.80 | -$47.20 | n/m |
| Dec 31, 2016 | $47.20 | — | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Zevra Therapeutics valuation against its peers
| Company | Market value | Price / sales |
|---|---|---|
| Zevra TherapeuticsZVRA | $608M | 4.5 |
| Candel TherapeuticsCADL | $610M | — |
| Solid BiosciencesSLDB | $610M | — |
| Olema PharmaceuticalsOLMA | $611M | — |
| Anteris Technologies GlobalAVR | $614M | 273.9 |
| Bicara TherapeuticsBCAX | $600M | — |
| Myriad GeneticsMYGN | $600M | 0.7 |
| 4D Molecular TherapeuticsFDMT | $622M | 6.8 |
| Fulgent GeneticsFLGT | $586M | 1.8 |
| Peer median | 4.3 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ZVRA financials · ZVRA returns
No forecast, no recommendation. This page describes Zevra Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.